| Doing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in Nigeria YK Avong, P Isaakidis, SG Hinderaker, R Van den Bergh, E Ali, ... PLoS One 10 (3), e0120161, 2015 | 55 | 2015 |
| Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study YK Avong, B Jatau, R Gurumnaan, N Danat, J Okuma, I Usman, D Mordi, ... PLoS One 13 (8), e0200810, 2018 | 52 | 2018 |
| Integrating community pharmacy into community based anti-retroviral therapy program: A pilot implementation in Abuja, Nigeria YK Avong, GG Aliyu, B Jatau, R Gurumnaan, N Danat, GA Kayode, ... PloS one 13 (1), e0190286, 2018 | 33 | 2018 |
| Prevalence of hypertension among patients aged 50 and older living with human immunodeficiency virus P Dakum, GA Kayode, A Abimiku, YK Avong, J Okuma, E Onyemata, T Ali, ... Medicine 98 (15), e15024, 2019 | 14 | 2019 |
| Procurement and supply management system for MDR-TB in Nigeria: Are the early warning targets for drug stock outs and over stock of drugs being achieved? B Jatau, Y Avong, O Ogundahunsi, S Shah, K Tayler Smith, ... PloS one 10 (6), e0128500, 2015 | 13 | 2015 |
| Adherence to anti-retroviral therapy in north central Nigeria Y Kambai Avong, B van Wyk, J Njab, G Abimiku, N Ndembi, J Okuma, ... Current HIV research 13 (4), 268-278, 2015 | 11 | 2015 |
| Prevalence and risk factors for obesity among elderly patients living with HIV/AIDS in a low-resource setting P Dakum, YK Avong, J Okuma, T Sorungbe, B Jatau, N Nedmbi, ... Medicine 100 (15), e25399, 2021 | 9 | 2021 |
| Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis EW Tiemersma, I Ali, A Alemu, YK Avong, A Duga, C Elagbaje, A Isah, ... BMC health services research 21, 1-12, 2021 | 8 | 2021 |
| Prevalence of adverse drug reactions to second line anti tuberculosis drugs in Nigeria: a cross-sectional study AA Ganiyu, YK Avong, A Akinyede, OM Ige | 5 | 2021 |
| Cohort Profi le: The Nigerian HIV Geriatric Cohort Study P Dakum, YK Avong, MK Odutola, J Okuma, GA Kayode, IE Nta, ... | 3* | |
| Treatment outcomes in a community pharmacy anti-retroviral therapy programme YK Avong, GA Kayode, EB Avong, B Jatau, C Mensah, P Dakum JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23, 82-82, 2020 | 2 | 2020 |
| Operation Save the World from Adverse Drug Reactions: findings from a drug safety surveillance programme in Nigeria YK Avong, B Jatau, GA Kayode, B Ukpabi, EB Avong, J Okuma, D Mordi, ... The Lancet Global Health 7, S46, 2019 | 2 | 2019 |
| Providing antiretroviral therapy outside the hospital in a low-resource setting: a pilot study YK Avong, GA Kayode, B Jatau, EB Avong, V Adekanmbi, A Abimiku, ... The Lancet Global Health 6, S3, 2018 | 1 | 2018 |
| Clients and Health Workers’ Perception of Community Pharmacy Based Anti-retroviral Therapy Model in Federal Capital Territory, Abuja, Nigeria FY Agwo, YK Avong, GA Akaa Acta Scientific MEDICAL SCIENCES (ISSN: 2582-0931) 6 (10), 2022 | | 2022 |
| Effect of mobile applications on the spontaneous reporting of adverse drug reactions: A systematic review and meta-analysis YK Avong, R Cutler, GA Kayode, V Adekanmbi, OA Uthman, K Rogers, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 657-658, 2022 | | 2022 |
| Oral Presentation: Nigeria is Making Progress Implementing the Active Drug Safety Monitoring and Management Scheme for New and Repurposed Antituberculosis Drugs YK Avong, AS Abiodun, B Jatau, AT Shuibu, C Elagbaje, A Opadeyi, I Ali, ... Drug Safety 44 (12), 1395-1395, 2021 | | 2021 |
| The Nigerian HIV geriatric cohort study. P Dakum, YK Avong, MK Odutola, J Okuma, GA Kayode, IE Nta, ... | | 2020 |
| Cohort Profile: The Nigerian HIV Geriatric Cohort Study GA Kayode, P Dakum, YK Avong, MK Odutola, J Okuma, IE Nta, ... | | 2019 |
| Adherence to anti-retroviral therapy in the federal capital territory, Abuja, Nigeria YK Avong | | 2012 |
| Fixed dose combination anti-retroviral drugs had comparable immunological, virological and adherence potential with single drug combinations YK Avong | | |
